Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Erwin L J Hoogervorst

Showing results (11-20 of 15) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 15 results.
Neurology|July 22, 2020
Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trialZoé L E van Kempen, Erwin L J Hoogervorst, Mike P Wattjes, et al.
International Journal of Molecular Sciences|October 14, 2022
Whole Exome Sequencing in Multi-Incident Families Identifies Novel Candidate Genes for Multiple SclerosisJulia Horjus, Tineke van Mourik-Banda, Marco A P Heerings, et al.
JAMA Neurology|December 9, 2024
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical TrialEline M E Coerver, Wing Hee Fung, Janet de Beukelaar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
European Journal of Neurology|July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of OcrelizumabLaura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.
Pageof 2

Showing results (11-20 of 15) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 15 results.
Neurology|July 22, 2020
Personalized extended interval dosing of natalizumab in MS: A prospective multicenter trialZoé L E van Kempen, Erwin L J Hoogervorst, Mike P Wattjes, et al.
International Journal of Molecular Sciences|October 14, 2022
Whole Exome Sequencing in Multi-Incident Families Identifies Novel Candidate Genes for Multiple SclerosisJulia Horjus, Tineke van Mourik-Banda, Marco A P Heerings, et al.
JAMA Neurology|December 9, 2024
Discontinuation of First-Line Disease-Modifying Therapy in Patients With Stable Multiple Sclerosis: The DOT-MS Randomized Clinical TrialEline M E Coerver, Wing Hee Fung, Janet de Beukelaar, et al.
Journal of Neurology, Neurosurgery, and Psychiatry|March 25, 2025
Low natalizumab trough concentrations are associated with reduced seroconversion of the John Cunningham virus in natalizumab-treated patients with multiple sclerosisLiza M Y Gelissen, Alyssa A Toorop, Pien M Schipper, et al.
European Journal of Neurology|July 7, 2026
Individual Variability of CD19+ B-Cell Repopulation in People With Multiple Sclerosis Treated With Extended Interval Dosing of OcrelizumabLaura Hogenboom, Lisa G Schoof, Liza M Y Gelissen, et al.
Pageof 2